Methods of treating autoimmune disease via CTLA-4Ig
US6685941B1 · kind B1 · utility
34Cited by
13References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 7, 1995 |
| Grant date | Feb 3, 2004 |
| Priority date | — |
| Expiry date | Feb 7, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.